```html

Zollner’s Disease (Erythropoietic Protoporphyria)

Overview

Zollner’s disease is the historical eponym for erythropoietic protoporphyria (EPP), a rare inherited disorder of heme synthesis. The condition results from a deficiency of the enzyme ferrochelatase that normally inserts iron into protoporphyrin IX to form heme. When this step is blocked, protoporphyrin accumulates in red‑blood‑cell precursors, the skin, and the liver.

• Who it affects: EPP can affect males and females of any ethnicity, but because it is usually inherited in an autosomal‑recessive or autosomal‑dominant pattern with reduced penetrance, it most often appears in childhood or early adolescence.
• Prevalence: Worldwide estimates range from 1 in 75,000 to 1 in 200,000 individuals, making it one of the more common types of cutaneous porphyrias.<sup>[1] NIH National Library of Medicine</sup>
• Typical age of onset: 1–10 years for classic “photosensitivity” type; liver complications usually appear later in adulthood.

Symptoms

The hallmark of EPP is an acute, non‑blistering photosensitivity that begins within minutes of exposure to visible light (especially sunlight). The symptom profile can be divided into cutaneous, systemic, and hepatic manifestations.

Cutaneous manifestations

• Burning, stinging, or itching within 5–30 minutes of sun exposure.
• Redness (erythema) and swelling of the exposed skin that may last several hours.
• Shadows and patterns (e.g., “coat‑of‑arms” effect) often appear where clothing or objects blocked light; these areas feel less painful.
• Hyperpigmentation or hypopigmentation after repeated attacks, especially on the face, hands, and forearms.
• Facial edema – noticeable swelling around the eyes and cheekbones after prolonged outdoor activities.
• Absence of blisters – unlike other photosensitivity disorders, EPP does not cause vesicles or bullae.

Systemic manifestations

• Fatigue and malaise after severe phototoxic episodes.
• Transient abdominal discomfort (reported in up to 20 % of patients) that is not directly related to liver disease.

Hepatic manifestations

• Elevated liver enzymes (ALT, AST, GGT) in 5–10 % of patients.
• Gallstones – formation of pigment gallstones due to excess protoporphyrin excretion.
• Progressive liver fibrosis or cirrhosis – occurs in ≈5 % of individuals, usually after age 30.<sup>[2] Cleveland Clinic</sup>
• Acute liver failure – rare but life‑threatening; presents with jaundice, coagulopathy, and encephalopathy.

Causes and Risk Factors

EPP is a disorder of the heme biosynthetic pathway. The primary cause is a mutation in the FECH gene (chromosome 18q21.3) that encodes ferrochelatase. About 90 % of cases involve reduced ferrochelatase activity; the remaining are due to gain‑of‑function mutations in the ALAS2 gene (X‑linked) that increase protoporphyrin production.

Genetic inheritance patterns

• Autosomal‑recessive – two defective copies of FECH (most common). Carriers (heterozygotes) are usually asymptomatic.
• Autosomal‑dominant with low penetrance – one mutant allele plus a common low‑expression polymorphism (c.315‑48T>C) leads to disease in about 50 % of carriers.
• X‑linked – ALAS2 gain‑of‑function mutations cause a subtype called “X‑linked protoporphyria”.

Risk factors

• Family history of EPP or unexplained photosensitivity.
• Carriage of low‑expression FECH polymorphisms combined with a pathogenic mutation.
• Co‑existing liver disease or alcohol use – may accelerate hepatic complications.
• Geographic location with high sun exposure (e.g., low‑latitude regions) increases the frequency of phototoxic episodes.

Diagnosis

Because the symptoms resemble other photodermatoses, a systematic approach is essential.

Clinical evaluation

• Detailed history of symptom onset, pattern of light‑induced pain, and family history.
• Physical examination focusing on sun‑exposed skin and signs of liver disease.

Laboratory tests

• Plasma and erythrocyte protoporphyrin levels – markedly elevated (often >1 µmol/L; normal <0.4 µmol/L). Free protoporphyrin (unbound to zinc) predominates.
• Urine porphyrin analysis – usually normal or only mildly increased, helping differentiate from other porphyrias.
• Liver function tests (LFTs) – ALT, AST, GGT, bilirubin.
• Genetic testing – sequencing of FECH and, if negative, ALAS2. Detects >95 % of pathogenic variants.

Specialist investigations

• Skin phototesting – measured decrease in minimal erythema dose (MED) to visible light.
• Abdominal ultrasound or elastography – evaluates liver architecture when LFTs are abnormal.
• Liver biopsy – rarely required; shows bile‑pigmented canalicular deposits of protoporphyrin.

Treatment Options

Management focuses on reducing phototoxic episodes, controlling liver disease, and improving quality of life.

Sun‑avoidance strategies (first‑line)

• Wear tightly‑woven UPF 50+ clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Apply broad‑spectrum sunscreen that blocks both UVA and visible light (e.g., zinc‑oxide or titanium‑dioxide formulations). Reapply every 2 hours.
• Schedule outdoor activities for early morning or late afternoon when ambient visible light intensity is lowest.
• Use window films that block >99 % of visible light for cars and homes.

Pharmacologic therapy

• Beta‑carotene (30–60 mg/day) – provides photoprotection by quenching singlet oxygen; clinical trials show ~50 % reduction in pain episodes.<sup>[3] Mayo Clinic</sup>
• Afamelanotide (Scenesse®) – a synthetic α‑MSH analogue that stimulates melanin production. FDA‑approved (2020) for EPP; subcutaneous implant improves tolerance to sunlight by 2–3 hours on average.<sup>[4] FDA</sup>
• Iron supplementation – indicated only if iron deficiency is documented; paradoxically, excess iron can worsen protoporphyrin accumulation, so routine supplementation is not recommended.
• Cholestyramine or other bile‑acid sequestrants – used in patients with liver involvement to increase fecal excretion of protoporphyrin.

Liver‑directed interventions

• Regular monitoring of LFTs every 6–12 months.
• Low‑dose ursodeoxycholic acid (UDCA) to improve bile flow.
• In advanced cirrhosis: referral for liver transplantation. Outcomes are favorable but require careful pre‑transplant management of phototoxicity.<sup>[5] WHO</sup>

Emerging therapies

• Gene‑editing (CRISPR/Cas9) trials – early‑phase studies aim to correct FECH mutations; still investigational.
• RNA interference (RNAi) targeting ALAS2 – under evaluation for X‑linked protoporphyria.

Living with Zollner’s Disease (Erythropoietic Protoporphyria)

Successful daily management combines medical treatment with practical lifestyle adjustments.

Practical tips

• Keep a symptom diary – record light exposure, pain intensity, and response to beta‑carotene or afamelanotide. This helps tailor preventive measures.
• Carry a “photo‑emergency kit” – sunscreen, protective clothing, a small tube of 5‑% zinc‑oxide cream, and a copy of your medication regimen.
• Hydrate well – adequate water intake supports biliary excretion of protoporphyrin.
• Nutrition – a balanced diet low in alcohol and saturated fats reduces liver stress. Some clinicians suggest modest amounts of vitamin C to aid antioxidant defenses.
• Workplace accommodations – request indoor lighting with reduced blue‑light emission or provide personal protective equipment.
• Psychosocial support – joining support groups (e.g., Porphyria Foundation) can help cope with the social limitations caused by photosensitivity.

Follow‑up schedule

• Dermatology visit: every 6–12 months or after any change in photosensitivity.
• Hepatology check: annually, or sooner if LFTs become abnormal.
• Genetic counseling: recommended for all patients and at‑risk family members.

Prevention

Because EPP is genetic, primary prevention of the disease is not possible. However, secondary prevention—reducing disease expression and complications—is achievable.

• Early genetic testing of siblings when a pathogenic variant is identified.
• Prompt initiation of photoprotective measures in children diagnosed before symptom onset.
• Avoidance of known liver toxins (excess alcohol, certain antibiotics, herbal hepatotoxins).
• Vaccination against hepatitis B to minimize additional hepatic stress.

Complications

If left untreated or poorly managed, EPP can lead to serious health issues.

• Progressive liver disease – fibrosis, cirrhosis, and eventual liver failure.
• Gallstone formation – may cause biliary colic or cholecystitis.
• Secondary skin changes – chronic hyperpigmentation, scarring, and psychosocial impact.
• Risk of vitamin D deficiency due to avoidance of sunlight; monitor levels annually.
• Quality‑of‑life impairment – anxiety, depression, and limitations in education or employment.

When to Seek Emergency Care

References

1. National Institutes of Health (NIH) – GeneReviews: Erythropoietic Protoporphyria, 2023.
2. Cleveland Clinic. “Hepatic Manifestations of Porphyria.” Updated 2022.
3. Mayo Clinic. “Beta‑carotene for Erythropoietic Protoporphyria.” Clinical guidelines, 2021.
4. U.S. Food & Drug Administration. “Afamelanotide (Scenesse) – FDA Approval Letter.” 2020.
5. World Health Organization (WHO). “Liver Transplantation in Metabolic Disorders.” 2022.

```